Oncology has a “toolbox surplus” but a “systems thinking deficit.”

Science increasingly shows cancer behaves like a complex, adaptive biological system (heterogeneous, evolving, shaped by microenvironment + host immunity). But the care and innovation system still behaves as if cancer is a linear, targetable object - and as if diagnosis and local interventions are mostly neutral steps before “real treatment.”

Examples of the mismatch

• We treat a tumor like a static target, yet it behaves like an evolving ecosystem: subclones expand, phenotypes switch, and the microenvironment rewires under pressure.

• We develop “the best drug” for a mutation, while patients fail because the tumor is immune-excluded, hypoxic, or physically inaccessible.

• We generate lots of data (NGS, imaging, biomarkers), but the clinical pathway has limited ability to convert that data into adaptive actions over time.

So we keep optimizing ingredients (drugs) while under-investing in orchestration (strategy, sequencing, local control, immune preservation, adaptive monitoring) - even though outcomes are often determined by the system’s response over time.

What is broken

The oncology system is organized around “variant → drug” logic, while cancer is organized around adaptation, context, and time - creating predictable gaps in standard-of-care (SOC).

Examples of “variant → drug” blind spots

• Biomarker says “PD-L1 low” → “not a candidate,” despite mixed tumor regions where invasive margins may be immunologically active.

• Biomarker says “PD-1/PD-L1 high” → “a candidate,” but microbiome composition (e.g., low beneficial bacteria Akkermansia muciniphila and others) blocks immune response.

• Mutation says “targetable” → therapy given, but drug cannot penetrate the stroma/hypoxia and never achieves effective exposure.

• A response is achieved → everyone relaxes, but resistant clones are being selected in parallel.

Why the current model predictably underperforms

1. Cancer is multi-pathway and redundant

Single agents can shrink tumors, but the system re-routes (feedback loops, clonal selection, phenotypic switching). Durable control requires anticipating adaptation, not reacting to resistance.

2. Microenvironment governs whether drugs can work

Access, hypoxia, stroma, immune exclusion, metabolic constraints - these determine if therapies reach targets and if immune responses can be mounted.

3. Strategy beats ingredients

Same modalities can produce radically different outcomes depending on sequencing, timing, delivery route, and immune-state management.

4. Diagnosis and local care are not biologically neutral

Imaging radiation, biopsy trauma, inflammation, wound-healing programs, immune perturbation - these can shift host-tumor dynamics. Yet SOC rarely designs countermeasures or tracks biologic “cost.”

The system-level gaps

• Static decisions instead of closed-loop adaptation.

• Siloed modalities without an orchestration layer.

• Sparse real-time monitoring of host integrity (immune competence, inflammatory state) despite its role in metastasis control.

• Combinations exist, but are validated as static recipes, not dynamically evaluated for immune compatibility, sequencing effects, or cumulative biologic harm.

• Guideline bias toward precedent rather than biological reality - what’s measurable and standardized wins over what’s causally important.

How this shows up in Ewing Sarcoma

Ewing Sarcoma makes the mismatch obvious because:

• The primary driver (EWS-FLI1) is effectively “undruggable,” so drug-centric logic stalls at the center of the disease.

• The disease is highly metastatic and immune/microenvironment sensitive, so host integrity and timing matter.

• SOC is multimodal and intense - yet often tracks toxicity crudely while missing key biology (lymphocyte dynamics, immune suppression patterns, inflammatory cascades).

Ewing is not just hard because the tumor is aggressive; it is hard because the system lacks an orchestration layer that treats diagnosis + local control + immune preservation as part of the therapy.

The “real” problem statement

We are fighting an adaptive biological system with a care model optimized for isolated interventions.

This creates SOC vulnerabilities where:

• we trigger biology (biopsy, radiation, delay) without countermeasures,

• we stack modalities without system-level immune stewardship, and

• we measure tumor response more than we measure the host’s capacity to prevent relapse and metastasis.

The opportunity

The next wave of oncology innovation is less about a single breakthrough drug and more about:

• orchestrating existing modalities,

• local-first and microenvironment-enabling strategies, and

• closed-loop, real-time adaptation that treats host integrity as a first-class clinical endpoint.

A strong “north star”

Build oncology for the system cancer actually is - adaptive, contextual, time-dependent - by shifting from product optimization to strategy orchestration.

The problem: innovation outpacing evaluation

Oncology innovation is moving faster than the systems designed to evaluate it. New therapies are still tested, approved, and delivered through clinical, regulatory, and economic frameworks that have evolved far more slowly than the science itself.

When novel approaches struggle to validate under these conditions, this does not necessarily reflect failure of the biology. More often, it reflects a system not yet fully designed to test what these strategies actually change and deliver.

Intratumoral immunotherapy brings this mismatch into focus. Instead of adding another systemic agent, these approaches change where, when, and how immune modulation is applied, exposing limits of frameworks optimized for isolated agents rather than access-dependent, procedure-mediated strategies.

From product innovation to system disruption

Oncology trials have long been optimized around a narrow question: does a specific agent work? Intratumoral immunotherapy reframes that question entirely, asking whether disease trajectory can be altered by reprogramming the tumor–immune ecosystem through access, timing, and sequencing.

Where traditional oncology innovation is product-centric - discovering molecules, validating targets, delivering systemically, and escalating on failure - intratumoral immunotherapy operates on a different logic. It begins with tumor access, focuses on local microenvironmental change, engages the immune system at the source, and seeks to preserve systemic capacity.

These are not incremental adjustments in concept, even if their implementation remains constrained by existing systems.

Positioning within innovation frameworks

In practice, intratumoral immunotherapy today coexists with systemic therapy, relies on existing drugs and institutions, is evaluated through legacy drug-like endpoints, lacks broad reimbursement and infrastructure redesign, and is often tested in late-line settings that obscure orchestration value. Adoption remains uneven and niche.

And yet, disruption is already underway. These approaches are beginning to reshape workflows around access-first delivery, introducing immune-aware and multi-modal metrics, elevating procedural immuno-oncology as a core capability, and shifting value from isolated molecules toward strategy and delivery.

They can become truly radical if local-first care becomes the default, systemic therapy becomes conditional, regulatory models evolve to approve strategies rather than drugs, hospitals reorganize around access and orchestration, and training pipelines adapt accordingly.

At that point, intratumoral immunotherapy would not just disrupt oncology - it would redefine it.

How the disruption unfolds

1) Clinical workflow: toward treat-at-access

What breaks: The assumption that diagnosis and biopsy must be separated from treatment by weeks or months through fragmented specialty handoffs, reflecting an infusion-era model in which therapy begins only after staging and onboarding.

What replaces it: Integrated workflows linking imaging, access planning, local delivery, and monitoring, supporting the development of treat-at-access models where diagnosis, sampling, local intervention, and immune priming occur within a single coordinated window (not necessarily the same day).

Why it matters: Waiting periods compress, biologically vulnerable gaps between diagnosis and treatment shrink, and tumor access itself becomes a therapeutic opportunity.

2) Care timing: from late rescue to orchestration

What breaks: Stepwise escalation that treats timing as a scheduling artifact rather than a biological variable.

What replaces it: Orchestration strategies that deliberately sequence local modulation and systemic therapy to shape immune dynamics.

Why it matters: Timing becomes part of the intervention, because late-line trials may understate value when immune education is timing-sensitive.

3) Delivery model: targeted concentration with systemic potential

What breaks: The assumption that efficacy requires whole-body drug exposure.

What replaces it: Localized delivery that achieves high tumor-site concentration with reduced systemic exposure, altered toxicity constraints, and in situ vaccination with possible system effects.

Why it matters: Combination strategies can be built around local intensity and systemic sparing rather than systemic maximum tolerability ceilings that limit what can be combined.

4) Capabilities, infrastructure, and team structure

What breaks: The traditional separation between oncology, surgery, interventional care, and immunology, reinforced by fragmented infrastructure and sequential specialist handoffs.

What replaces it: Hybrid teams and integrated platforms combining image-guided access, immunobiology, tissue handling, immune and longitudinal monitoring.

Why it matters: Execution and orchestration - not just drugs - become the differentiators and shift oncology toward a systems discipline.

5) Surgery and local procedures: from removal to orchestration

What breaks: The framing of local therapy as cytoreduction alone, with procedures treated as independent of immune strategy.

What replaces it: Strategic use of local intervention to shape immune biology in coordination with systemic therapy, extending existing surgical strategy by explicitly incorporating immune modulation as a primary objective.

Why it matters: Local therapy shifts from reducing burden to changing biology, potentially increasing systemic leverage and durability when paired appropriately.

6) Value creation: from molecules to strategies

What breaks: Value defined by ownership of a chronically dosed systemic molecule.

What replaces it: Value concentrates in strategies that control access, delivery, sequencing, and monitoring, shifting differentiation toward platforms and care logic rather than isolated agents.

Why it matters: This suggests a potential shift in where competitive advantage may ultimately accrue - from ‘best drug wins’ toward ‘best strategy wins’ - with implications for reimbursement and the economics of immunotherapy.

7) Hospital economics and incentives

What breaks: Current hospital care pathways and revenue structures are largely optimized around infusion throughput, recurring visits, prolonged treatment cycles, and management of systemic toxicity.

What replaces it: Intratumoral and access-based strategies may favor care pathways with fewer infusions and systemic side effects, shorter waiting windows, and greater reliance on procedure- and coordination-intensive workflows.

Why it matters: Even if clinical outcomes are comparable, shifts in where time, labor, and reimbursement pressure accumulate could require institutional adaptation and may create adoption friction independent of biological performance.

8) Metrics and endpoints: beyond scan response

What breaks: The reliance on stepwise escalation and static imaging shrinkage as the primary indicators of success.

What replaces it: Strategy-level evaluation and expanded endpoint frameworks that pair imaging with longitudinal, lesion-specific, and immune-aware measurements over time.

Why it matters: These measurements begin to support earlier biological insight and adaptive strategy design, creating a pathway toward intervention that responds to immune dynamics rather than waiting for late-stage failure after immune exhaustion.

Patient experience: where the value shows up first

For many patients, the impact of intratumoral and access-based strategies is felt early - not as a breakthrough moment, but as a different experience of care from the start. When tumors are accessible and immune conditions are favorable, care can unfold differently from the start.

In those settings, patients may experience:

• Earlier, more intentional intervention, with diagnosis, sampling, and initial treatment more tightly coordinated - reducing prolonged waiting periods and potentially contributing to earlier biological control in selected contexts.

• Biology-driven decision-making, where patients understand why a local procedure is performed, how it contributes to immune modulation, and which biological signals are being monitored over time.

• Reduced systemic exposure in some regimens, translating into fewer or more localized side effects compared with fully systemic therapy and expanding tolerability for combination approaches.

• More targeted, access-based interventions, which in certain settings may be less invasive than extensive surgery, enabling faster recovery and earlier return to daily activities.

• Strategic rather than reactive treatment courses, replacing trial-and-error escalation with a coherent plan that integrates local and systemic therapy from the outset.

• Less aggressive treatment trajectories in selected cases, where local modulation and immune priming may delay, reduce, or avoid the need for high-intensity systemic or surgical interventions.

These shifts do not promise uniform benefit or guaranteed outcomes. Instead, they reflect care that can feel more purposeful, more coherent, and better aligned with biology and timing.

Conclusion

Intratumoral immunotherapy exposes a recurring tension in oncology innovation. Approaches that reorganize access, delivery, and coordination may generate meaningful biological effects, yet struggle within evidence models designed for systemic agents and discrete products.

The challenge is not simply proving efficacy, but developing validation frameworks capable of assessing system-level strategies. Until those frameworks mature, translation of intratumoral - and similar - approaches will likely remain slower and more fragile than their scientific rationale alone would predict.

Modern oncology is rich in tools but constrained by models. When cancer behaves as a complex, adaptive system, linear approaches built around isolated interventions predictably fall short.

Below are six core insights reshaping oncology, and why the next decade will look very different from the last.

1. Single agents fail because cancer is multi-pathway and adaptive

Cancer rarely depends on a single pathway, mutation, or signal. It survives through:

• redundancy (backup survival routes),

• feedback loops (systems that re-stabilize under pressure),

• heterogeneity (different regions behaving differently),

• evolution under therapy (resistant clones expanding).

This makes single-agent approaches inherently insufficient. Short-term responses are common; durable control is not.

Key Insight: Outcomes are determined less by what is targeted than by how the system responds over time.

Innovation implication: Progress shifts from “stronger drugs” toward multi-axis strategies designed to anticipate adaptation across immune, metabolic, and microenvironmental axes - rather than reacting to resistance after it emerges.

2. Diagnosis is an early biological intervention, not a neutral observation

Imaging, biopsy, and biomarker testing can alter the biology they aim to describe. Diagnosis is not a passive prelude to treatment; it is already part of the intervention timeline.

Imaging

• CT and PET involve ionizing radiation.

• Repeated imaging represents cumulative biological stress and DNA damage, not free information.

Biopsy

Biopsy is necessary, but it can trigger:

• wound-healing responses and inflammation,

• immune–stromal remodeling, including recruitment and activation of suppressive myeloid programs,

• microenvironmental changes that may favor invasion or escape in some contexts.

In some cancers, delays of more than ~53 days between biopsy and definitive treatment have been associated with higher metastatic risk.

Key Insight: Diagnostic access introduces biological risk and must be paired with countermeasures.

Innovation implication: Innovation shifts from optimizing individual tests to designing integrated diagnostic–interventional pathways—evaluated for biological impact (tumor biology, immune function, inflammation, treatment readiness), not just informational value.

3. Biomarkers are helpful - but not guarantees

Biomarkers (PD-1/PD-L1, MSI, TMB, ctDNA, etc.) are signals, not certainties. They should inform dynamic, closed-loop strategies rather than act as fixed truths.

Results mislead because of:

• Heterogeneity: Hot and cold regions coexist within the same tumor, each governed by different biology and requiring different interventions.

• Sampling bias: A single biopsy rarely represents the full tumor ecosystem. Samples are typically taken from the tumor core, while biologically relevant signals e.g., PD-L1 expression are often enriched at invasive margins—explaining why some patients respond despite unfavorable biomarker profiles.

• Adaptive resistance: “Positive” signals may reflect active defense mechanisms rather than therapeutic vulnerability, explaining why some patients do not respond despite favorable biomarker profiles.

• Override biology: Immune suppression, metabolic constraints, stromal barriers, and microbiome effects can block response to most novel drugs despite favorable biomarkers.

Key Insight: Biomarkers should function as decision support within a broader strategy, designed at the micro-ecosystem level rather than the patient-average level.

Innovation implication: Innovation shifts from using biomarkers to select patients or therapies to using them to steer adaptive, micro-ecosystem–level strategies over time.

4. The tumor microenvironment decides whether drugs can work

“Cold vs hot” (immune-excluded vs immune-infiltrated) often predicts immunotherapy success as much as - or more than - the drug choice.

Vascular access, stromal barriers, metabolic constraints, and immune suppression can render even advanced therapies ineffective.

Key Insight: Response is determined by the microenvironment and where and how therapy is delivered, not only by what is delivered.

Innovation implication: Enabling response often requires modifying the microenvironment. Local therapies such as PEF, cryoablation, or radiation can convert non-responsive regions into immunologically active ones.

5. Strategy matters more than ingredients

The same tools, applied differently, can produce radically different outcomes. In adaptive systems, results depend less on individual components than on how they are combined, sequenced, and delivered.

Key Insight: Execution logic and strategy outweigh ingredient selection.

Innovation implication: Competitive advantage moves from individual products to orchestration - with sequencing, timing, delivery, and immune preservation becoming the primary innovation surface.

6. Early, local intervention may prevent systemic failure

Systemic disease often reflects local immune failure that persisted too long.

Tumor-directed and intratumoral immunotherapies engage the immune system earlier - at the site where dysfunction originates - with the aim to educate immunity before exhaustion, escape, and dissemination dominate.

Key Insight: Systemic progression is often the downstream consequence of uncorrected local immune failure.

Innovation implication: Shifting from systemic-first to local-first strategies fundamentally changes the therapeutic landscape.

What changes when these insights are taken seriously?

Innovation priorities shift:

• from tumor-centric to system-centric,

• from isolated products to strategic combinations,

• from static decisions to dynamic adaptation,

• from escalation to early orchestration,

• from “best drug” to best strategy.

Closing perspective

Cancer is not a single enemy to eliminate. It is a complex adaptive system responding to pressure, context, and time.

The next breakthroughs will not come from one miracle drug.They will come from better orchestration of what we already have.

The opportunity is not just new therapies, it is a new way of thinking.